BlackRock
DNA icon

BlackRock’s Ginkgo Bioworks DNA Stock Holding History

BlackRock’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4M Buy
4,282,903
+640,556
+18% +$5.36M ﹤0.01% 2773
2026
Q1 		$22.3M Buy
3,642,347
+68,978
+2% +$574K ﹤0.01% 3018
2025
Q4 		$29.7M Buy
3,573,369
+155,373
+5% +$1.67M ﹤0.01% 2852
2025
Q3 		$49.8M Buy
3,417,996
+367,800
+12% +$4.4M ﹤0.01% 2497
2025
Q2 		$34.3M Buy
3,050,196
+1,808,161
+146% +$14M ﹤0.01% 2695
2025
Q1 		$7.08M Sell
1,242,035
-46,563
-4% -$474K ﹤0.01% 3487
2024
Q4 		$12.7M Buy
1,288,598
+202,211
+19% +$1.73M ﹤0.01% 3299
2024
Q3 		$8.85M Buy
1,086,387
+36,116
+3% +$362K ﹤0.01% 3468
2024
Q2 		$14M Sell
1,050,271
-771,281
-42% -$23M ﹤0.01% 3187
2024
Q1 		$84.5M Buy
1,821,552
+1,680
+0.1% +$87K ﹤0.01% 2151
2023
Q4 		$123M Buy
1,819,872
+2,390
+0.1% +$146K ﹤0.01% 1959
2023
Q3 		$132M Buy
1,817,482
+112,411
+7% +$8.99M ﹤0.01% 1829
2023
Q2 		$127M Buy
1,705,071
+438,469
+35% +$26M ﹤0.01% 1885
2023
Q1 		$67.4M Buy
1,266,602
+90,203
+8% +$5.72M ﹤0.01% 2266
2022
Q4 		$79.5M Buy
1,176,399
+399,079
+51% +$36.7M ﹤0.01% 2161
2022
Q3 		$97M Sell
777,320
-31,512
-4% -$3.76M ﹤0.01% 1987
2022
Q2 		$77M Buy
808,832
+410,000
+103% +$50M ﹤0.01% 2199
2022
Q1 		$64.3M Sell
398,832
-10,071
-2% -$1.96M ﹤0.01% 2429
2021
Q4 		$136M Buy
+408,903
New +$194M ﹤0.01% 2002

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BlackRock's DNA Position: Q2 2026 in Review

BlackRock increased its Ginkgo Bioworks (DNA) stake by 18% in Q2 2026, buying an estimated $5.36M and bringing the position to 4,282,903 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

BlackRock first reported a position in DNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $136M in Q4 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • BlackRock held 4,282,903 shares of Ginkgo Bioworks worth $42.4M as of Q2 2026.
  • BlackRock bought 640,556 Ginkgo Bioworks shares in Q2 2026, an estimated $5.36M.
  • Ginkgo Bioworks made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2773 holding.
  • BlackRock first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Ginkgo Bioworks position peaked at $136M in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.